ASCO-GI 2025 - Optimismus in San Francisco

Zusammenfassung

Auf dem ASCO GI 2025 gab es wieder einigen Anlass zum Optimismus. In den Late-Breaking Abstracts wurden gleich mehrere neue Studien präsentiert, die in ihrer jeweiligen Indikation das Potenzial besitzen, die Therapiestandards zu verändern. In der Diskussion zum prädiktiven Wert der ctDNA-Testung für die Wirksamkeit einer adjuvanten Chemotherapie sowie zum Tumorscreening gewinnen die Befürworter an Boden.

• Literatur

• 1 Kopetz S. et al. BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer. ASCO GI 2025 Abstract 16
• 2 Martling A. et al. Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial. ASCO GI 2025 Abstract LBA125
• 3 Andre T. et al. First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW. ASCO-GI 2025 Abstract LBA143
• 4 Leng X. et al. Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma. ASCO GI 2025 Abstract LBA329
• 5 Shah P. et al. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. Presented at ASCO GI 2025 Abstract 15
• 6 Nowak J. et al. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. ASCO GI 2025 Abstract LBA14
• 7 Shaukat A. et al. Performance of a blood-based test for colorectal cancer screening adjusted to the US census age and sex distribution. ASCO GI 2025 Abstract 18
• 8 Dotan E. et al. Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer. ASCO GI 2025 Abstract 676